ICD10

Computable Phenotypes for Identifying Patients with Lung and Gastroenteropancreatic Neuroendocrine Tumors in PCORnet

This phenotype specification supports the identification of patients with lung and gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) for the Neuroendocrine Tumors- Patient-Reported Outcomes Study (NET-PRO) - a multi-site, patient-centered outcomes research initiative (PCORI) funded study (RD-2020C2-20329) conducted within PCORnet.

Owner Phenotyping Groups: 
PCORI CDRN/PPRN
The University of Iowa
View Phenotyping Groups: 
PCORI CDRN/PPRN
The University of Iowa
Final

Febrile Neutropenia (Pediatric)

Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy, defined by fever occurring in the context of neutropenia. Prompt recognition and treatment are essential to reduce morbidity and mortality. This algorithm focuses on "high-risk" FN as defined in the ‘Early versus Late Stopping of Antibiotics in high-risk FN’ (ELSA-FN)  randomised control trial as expected absolute neutrophil count (ANC) <500 cells/mm3 for ≥7 days.

Owner Phenotyping Groups: 
Parkville Precinct
View Phenotyping Groups: 
Parkville Precinct
Final

SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria

Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease that can affect many parts of the body including skin, lungs, brain, heart, kidneys, joints, and blood vessels. SLE presentation can vary significantly between patients. Because of this, it can be challenging to identify a patient as having SLE. Between 300,000 and 2,000,000 people in the US are estimated to have SLE. Determination of an exact number of people affected is challenging as the disease is difficult to identify given the diverse presentations and the length of time it may take for symptoms to appear.

Owner Phenotyping Groups: 
eMERGE Northwestern Group
View Phenotyping Groups: 
eMERGE Mayo Group
eMERGE Phenotype WG
Final